Effect of SHP2 Inhibition on mRNA Expression Profiles of GIST Cells
Secondary mutation of KIT/PDGFRA is the main reason that contributes to the multi-drug resistance phenotype of advanced GIST in the clinical setting. SHP2 is a specific signal transducer of KIT. Therefore, the combination of approved KIT/PDGFRA kinase inhibitors and SHP2 inhibitors is a promising treatment strategy for advanced GIST patients. Here, we treated GIST cells with the SHP2 inhibitor SHP099 and sequenced the total mRNA to analyze the effect of SHP2 inhibition on GIST cells. Overall design: GIST cells were cultured in IMDM supplemented with 20% FBS. In the control group, cells were cultured for 24 hours. In the treatment group, cells were treated with SHP099 (20 µM) for 24 hours. Total mRNA was extracted, processed, and analyzed.